09.14.20 -- 5 Steps To Prepare For A Third-Party Drug Price Evaluation
Join this live discussion on the biopharma trends impacting your facility and business. BioPlan Associates’ Eric Langer will join FUJIFILM Diosynth Biotechnologies' Jonathan M. Haigh, Ph.D., and BioProcess Online’s Matt Pillar for an analysis of current events and a Q&A on development opportunities, hiring trends, new technology adoption, COVID-19, and more. Register.
Planning for and mitigating an external review requires proactive team preparation and is crucial to ensure drug success. Here are five steps to take to prepare for evaluations and ensure that your drugs receive reasonable price recommendations.
Unfortunately, Flexion’s incorporation coincided with the financial crisis of 2007 and 2008, and the assumption that large pharmas would pay premiums for successful proof of concept assets came under pressure.
Of 367 production plants BASF operates worldwide, six are Verbund sites. Those six produce more than 50 percent of all BASF volumes. A CEO of a U.S.-based CDMO thinks Verbund is the kind of thinking needed at drug development and manufacturing facilities in this country.
Sutro Biopharma’s CTO, Dr. Shabbir Anik, has contributed to 15 INDs and 10 NDA’s, making him a great choice to sit down for a chat with Business Of Biotech about the mechanics of GMP and CMC strategy in emerging biopharma enterprises. Listen now and subscribe so you never miss an episode.